Navigation Links
Study Offers Insights Into Treatment Of Rheumatoid Arthritis

It has been known for long that rheumatoid arthritis patients respond differently to the same treatment instituted. // The mechanism however remained unclear. A new study now explains that it is due to diversity in immune mechanisms. The results have been identified following experiments conducted on animal models of mouse that mimics the disease condition.

The identification of such complex behaviors could enable physicians make an individualized diagnosis of RA patients, eventually paving way for effective therapies against specific forms of the disease. There has been a considerable improvement in the identification of new therapies and a universal acceptance of the same over the past 20 years.

Rheumatoid arthritis (RA) is a chronic and crippling inflammatory joint, bone and cartilage disease affecting more than 2.1 million Americans. It is an autoimmune disorder that is characterized by inflammation of the lining of the joints, called the synovium.

Researchers have identified three distinct types of the disease. In diffuse RA, T and B-lymphocytes seem to infiltrate tissue randomly, re-sulting in autoimmune inflammation. In aggregate synovitis, T and B cells meet each other in aggregates and inflame the joints. In germinal center synovitis, T cells, B cells, and other supporting cell populations go into the joints and acquire a highly complex and organized micro-architecture that resembles conditions in an inflamed lymph node.

Two proteins, known as APRIL (A proliferation inducing ligand) and BlyS (B-lymphocyte stimulator) that are hypothesized to help B-lymphocytes survive and differentiate are the targets of new experimental drugs currently in early phase clinical trials.

The researchers implanted human tissue from RA patients who had the three different types of disease into the mice and treated it with the proteins. It was found that in mice with germinal center synovitis, there was a halt of the inflammatory process while in the other two groups there was an aggravation of the condition.

In conclusion, the two proteins have been found to have multiple and complex effects in rheumatoid arthritis. The goal of current RA treatment is to suppress the immune system. The present research study has pointed out to the necessity of identification of natural anti-inflammatory pathways that can be exploited.

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:

(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology: